Liraglutide effectiveness in type 2 diabetes: insights from a real-world cohort of Portuguese patients

• Autor(a) principal: Silva-Nunes, José
• Data de Publicação: 2022
• Outros Autores: Nascimento, Edite, Louro, Joana, Dores, Jorge, Laginha, Teresa, Gonçalves-Ferreira, Ana, Alves, Marta, Souto, Selma B., Cunha, Nelson, Pina, Elsa, Duarte, Rui, Raposo, João Filipe
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: http://hdl.handle.net/10400.21/15127
• topic: Anthropometric parameters; Cardiovascular risk factors; Glycemic control; Liraglutide; Real-world evidence; Diabetes type 2

Liraglutide is a long-acting glucagon-like peptide-1 receptor agonist prescribed to diabetic patients for glycaemic control. To understand the impact of liraglutide in the real-world setting, this study analysed its effects in a Portuguese cohort of Type 2 diabetes patients. This was an observational, multicentric, and retrospective study that included 191 liraglutide-treated patients with at least 12 months of treatment. Patients' data were collected and analysed during a 24-month follow-up period. Overall, liraglutide treatment effectively reduced HbA1c levels from 8.3% to around 7.5%, after 6, 12, and 24 months (p < 0.001). In fact, 38.2%, 37.2%, and 44.8% of patients at 6, 12, and 24 months, respectively, experienced an HbA1c reduction of at least 1%. Moreover, a persistent reduction in anthropometric features was also observed, with 44.0%, 47.6%, and 54.4% of patients achieving a weight reduction of at least 3% at 6, 12, and 24 months, respectively. Finally, significant improvements were observed in the HDL-c and LDL-c levels. Our results demonstrate that liraglutide effectively promoted the reduction of HbA1c values during routine clinical practice, which was sustained throughout the study. In addition, there were significant improvements in anthropometric parameters and other cardiovascular risk factors.